Pulmonology

Divay Chandra, MD, MSc, University of Pittsburgh, is evaluating whether higher circulating lithium levels are associated with emphysema in a new study.

Peter Miller, MD, PhD, from Massachusetts General Hospital and Harvard Medical School, is working to further uncover the role of clonal hematopoeisis in COPD.

Acute respiratory infection caused by RSV results in a nearly 3-fold increase in mortality, particularly in those with underlying respiratory conditions.

Our Q1 2025 recap for pulmonology spotlights 5 regulatory updates, 5 key trial announcements, and top expert perspectives in pulmonology care. Read now:

Lung cancer is still the leading cause of cancer deaths, but effective screening and early detection can decrease a person’s chance of dying by 20%.

Participants with higher baseline eosinophil levels had the greatest responses and no participants experienced peaks of over 3000 eosinophils/µL.

This March 2025 month in review covers key pulmonology updates, including new findings on pulmonary function tests and expert insights from the AAAAI/WAO Joint Congress.

Vallerie Mclaughlin, MD, discusses the ZENITH trial and its historic effects of sotatercept on mortality, transplant risk, and more in PAH.

Pulse oximeter bias was less negative in darkly pigmented skin, suggesting a difference in performance across skin pigment categories.

Treprostinil (YUTREPIA) was previously granted tentative approval on August 16, 2024.

A new cross-sectional study found that the odds of having bronchodilator responsiveness declined by 8% per hour during the working day.

By year 5, COPD exacerbations occurred in 81.3% of the PPV23 group and 23.6% of the PCV13 group.

Our top 5 headlines featured an oral drug delivering 16% weight loss, notable blood pressure reductions from a hypertension treatment, and 3 key FDA decisions.

Hoyte discussed findings from a post hoc analysis of the phase 3 NAVIGATOR study.

Chambliss also discussed other research she is working on looking to understand effects on children with asthma.

Lipworth shared findings from 2 studies that he presented data from at the AAAAI/WAO Joint Congress.

Chambliss and colleagues found a 1% increase in asthma-related emergency department visits per unit of distance to semiconductor fabrication plants.

This February 2025 month in review covers key pulmonology updates, including FDA reviews for brensocatib and PRGN-2012, dupilumab’s COPD data, and wildfire air quality risks.

Findings were presented from the AROMA registry study in 3 abstracts at the AAAAI,WAO Joint Congress.

Castells discusses improvements in symptoms and quality of life scores for patients with indolent systemic mastocytosis across >2 years of the PIONEER trial.

Castells describes what’s missing from the current treatment landscape and the potential implications of elenestinib for indolent systemic mastocytosis.

Subgroup analyses of the real-world REALITI-A study were presented at the 2025 AAAAI/WAO Joint Congress.

There was a 79% relative reduction in annualized asthma exacerbation rate in the 6 months after starting treatment compared with the prior 6 months.

This FDA News Month in Review provides a round-up of regulatory decisions from February 2025.